BRISTOL-MYERS SQUIBB CO (BMY)
US1101221083 - Common Stock
BMY gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. BMY has only an average score on both its financial health and profitability. BMY is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BMY was profitable.
BMY had a positive operating cash flow in the past year.
BMY had positive earnings in 4 of the past 5 years.
In the past 5 years BMY always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of BMY (-7.75%) is better than 73.44% of its industry peers.
The Return On Equity of BMY (-42.34%) is better than 61.46% of its industry peers.
BMY has a better Return On Invested Capital (13.86%) than 92.71% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BMY is significantly below the industry average of 42.20%.
The 3 year average ROIC (12.67%) for BMY is below the current ROIC(13.86%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.75% | ||
| ROE | -42.34% | ||
| ROIC | 13.86% |
ROA(3y)7.12%
ROA(5y)3.28%
ROE(3y)22.36%
ROE(5y)9.98%
ROIC(3y)12.67%
ROIC(5y)9.9%
1.3 Margins
BMY's Profit Margin has declined in the last couple of years.
BMY has a Operating Margin of 23.45%. This is amongst the best in the industry. BMY outperforms 91.15% of its industry peers.
BMY's Operating Margin has declined in the last couple of years.
BMY has a Gross Margin of 75.87%. This is amongst the best in the industry. BMY outperforms 83.33% of its industry peers.
BMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.45% | ||
| PM (TTM) | N/A | ||
| GM | 75.87% |
OM growth 3Y19.76%
OM growth 5Y-7.02%
PM growth 3YN/A
PM growth 5Y-3.95%
GM growth 3Y1.17%
GM growth 5Y1.35%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BMY is still creating some value.
BMY has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BMY has been increased compared to 5 years ago.
BMY has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.14 indicates that BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of BMY (2.14) is better than 69.79% of its industry peers.
The Debt to FCF ratio of BMY is 3.60, which is a good value as it means it would take BMY, 3.60 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BMY (3.60) is better than 90.10% of its industry peers.
A Debt/Equity ratio of 2.85 is on the high side and indicates that BMY has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.85, BMY is doing worse than 82.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.85 | ||
| Debt/FCF | 3.6 | ||
| Altman-Z | 2.14 |
ROIC/WACC1.59
WACC8.74%
2.3 Liquidity
A Current Ratio of 1.24 indicates that BMY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.24, BMY is doing worse than 81.77% of the companies in the same industry.
A Quick Ratio of 1.09 indicates that BMY should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.09, BMY is not doing good in the industry: 78.13% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
BMY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -84.65%.
Measured over the past years, BMY shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.51% on average per year.
BMY shows a small growth in Revenue. In the last year, the Revenue has grown by 5.56%.
Measured over the past years, BMY shows a quite strong growth in Revenue. The Revenue has been growing by 14.81% on average per year.
EPS 1Y (TTM)-84.65%
EPS 3Y5.21%
EPS 5Y13.51%
EPS Q2Q%-10%
Revenue 1Y (TTM)5.56%
Revenue growth 3Y1.91%
Revenue growth 5Y14.81%
Sales Q2Q%8.44%
3.2 Future
Based on estimates for the next years, BMY will show a decrease in Earnings Per Share. The EPS will decrease by -3.44% on average per year.
BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.54% yearly.
EPS Next Y-87.81%
EPS Next 2Y-2.84%
EPS Next 3Y-4.98%
EPS Next 5Y-3.44%
Revenue Next Year6.18%
Revenue Next 2Y2.37%
Revenue Next 3Y-0.43%
Revenue Next 5Y-1.54%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 50.32, BMY can be considered very expensive at the moment.
Based on the Price/Earnings ratio, BMY is valued a bit cheaper than 79.17% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.29, BMY is valued quite expensively.
BMY is valuated reasonably with a Price/Forward Earnings ratio of 8.32.
BMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMY is cheaper than 91.15% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BMY to the average of the S&P500 Index (24.01), we can say BMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.32 | ||
| Fwd PE | 8.32 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BMY is valued cheaply inside the industry as 90.10% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BMY is valued cheaper than 93.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.65 | ||
| EV/EBITDA | 7.54 |
4.3 Compensation for Growth
The decent profitability rating of BMY may justify a higher PE ratio.
A cheap valuation may be justified as BMY's earnings are expected to decrease with -4.98% in the coming years.
PEG (NY)N/A
PEG (5Y)3.72
EPS Next 2Y-2.84%
EPS Next 3Y-4.98%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.12%, BMY is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 4.28, BMY pays a better dividend. On top of this BMY pays more dividend than 95.83% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.19, BMY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
5.2 History
The dividend of BMY is nicely growing with an annual growth rate of 7.57%!
BMY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of BMY decreased in the last 3 years.
Dividend Growth(5Y)7.57%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
BMY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-66.2%
EPS Next 2Y-2.84%
EPS Next 3Y-4.98%
BRISTOL-MYERS SQUIBB CO
NYSE:BMY (11/22/2024, 8:26:32 PM)
After market: 58.83 -0.04 (-0.07%)58.87
+0.64 (+1.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap119.40B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.32 | ||
| Fwd PE | 8.32 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)3.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.75% | ||
| ROE | -42.34% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 23.45% | ||
| PM (TTM) | N/A | ||
| GM | 75.87% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.85 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-84.65%
EPS 3Y5.21%
EPS 5Y
EPS Q2Q%
EPS Next Y-87.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)5.56%
Revenue growth 3Y1.91%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y